SXC 2023

Drug Profile

SXC 2023

Alternative Names: SXC-2023

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Marquette University; University of Wisconsin at Milwaukee
  • Developer Promentis Pharmaceuticals
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action SLC7A11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psychiatric disorders

Most Recent Events

  • 20 Nov 2017 Promentis Pharmaceuticals has composition of matter patent protection for SXC 2023
  • 11 Sep 2017 Phase-I clinical trials in Psychiatric disorders (In volunteers) in USA (PO) (NCT03301298)
  • 30 Mar 2017 Preclinical trials in Psychiatric disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top